Brief: Obseva Submits New Drug Application To FDA For Linzagolix
15/09/2021 06:12
Sept 15 (Reuters) - OBSEVA SA OBSN.S :
* OBSEVA ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO
U.S. FDA
FOR LINZAGOLIX FOR THE TREATMENT OF UTERINE FIBROIDS
Source text for Eikon: ID:nGNEcg5Kry
Further company coverage: OBSN.S
(Gdansk Newsroom)
((Gdansk.Newsroom@thomsonreuters.com;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary